Izrael - hebrejčina - Ministry of Health

padagis israel agencies ltd, israel - dextromethorphan hydrobromide; guaifenesin - סירופ - dextromethorphan hydrobromide 10 mg / 5 ml; guaifenesin 100 mg / 5 ml - dextromethorphan - dextromethorphan - for relief of cough and expecctorant.

Izrael - hebrejčina - Ministry of Health

padagis israel agencies ltd, israel - dextromethorphan hydrobromide; guaifenesin - סירופ - dextromethorphan hydrobromide 10 mg / 5 ml; guaifenesin 100 mg / 5 ml - dextromethorphan - dextromethorphan - for relief of cough and expecctorant.

Izrael - hebrejčina - Ministry of Health

novartis israel ltd - nepafenac - תרחיף לעין - nepafenac 0.1 % - nepafenac - nepafenac - prevention and treatment of postoperative pain and inflammation associated with cataract surgery and reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Izrael - hebrejčina - Ministry of Health

novartis israel ltd - timolol as maleate; travoprost - תמיסה לעין - travoprost 40 mcg/ml; timolol as maleate 5 mg/ml - timolol, combinations - timolol, combinations - decrease of intraocular pressure (iop) in patients with open angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

Izrael - hebrejčina - Ministry of Health

novartis israel ltd - brinzolamide; timolol as maleate - תרחיף לעין - brinzolamide 10 mg/ml; timolol as maleate 5 mg/ml - timolol, combinations - timolol, combinations - decrease of intra-ocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.

Izrael - hebrejčina - Ministry of Health

novartis israel ltd - travoprost - תמיסה לעין - travoprost 0.004 %w/v - travoprost - travoprost - for the reduction of elevated intra ocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other iop lowering medications or insufficiently responsive to another iop lowering medication.

Izrael - hebrejčina - Ministry of Health

sanofi israel ltd - sevelamer carbonate anhydrous - אבקה להכנת תרחיף - sevelamer carbonate anhydrous 2.4 g/sachet - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney diseasenot on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Izrael - hebrejčina - Ministry of Health

trima israel pharmaceutical products maabarot ltd - aluminium chlorohydrate; undecenoic acid; zinc undecenoate - אבקה - undecenoic acid 3 g / 100 g; aluminium chlorohydrate 3 g / 100 g; zinc undecenoate 18 g / 100 g - other antifungals for topical use - for prophylaxis and treatment of fungal infections of the skin especially "athletes foot".

Izrael - hebrejčina - Ministry of Health

padagis israel agencies ltd, israel - ferrous sulfate - טבליה - ferrous sulfate 247.25 mg - iron bivalent, oral preparations - prevention and treatment of iron deficiency anemia.

Izrael - hebrejčina - Ministry of Health

novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.